A decade ago, a pharmacist squinting at a handwritten scrawl to guess whether it said “Celebrex” or “Cerebyx” was an everyday hazard. Today, in most parts of the country, that scenario is close to obsolete. Electronic prescribing — e-prescribing — has become the default way medications move from a clinician’s exam room decision to a pharmacy shelf, and a more recent extension of the technology, EPCS, has started doing the same for controlled substances like opioids and stimulants.

The shift didn’t happen overnight, and it didn’t happen for one reason. Federal incentive programs, state mandates responding to the opioid crisis, and plain operational convenience have all pushed adoption forward at different times and for different reasons. This piece walks through how e-prescribing actually works under the hood, what makes EPCS a distinct and more tightly regulated animal, and where the technology still has real limitations.

What Is E-Prescribing, Exactly?

E-prescribing is the process of a clinician creating, and electronically transmitting, a prescription directly from an electronic health record (EHR) or standalone prescribing application to a pharmacy’s dispensing system — without a paper printout, a phone call, or (ideally) a fax machine in between.

At its core, e-prescribing depends on three things working together:

  • A prescriber-facing application — usually a module inside an EHR — where the clinician selects the drug, dose, quantity, and directions.
  • A transaction standard that puts that prescription into a structured, machine-readable format both the sender and receiver understand.
  • A network that routes the transaction to the correct pharmacy and can carry information back the other way.

In the United States, the transaction standard used almost universally for this purpose is the NCPDP SCRIPT standard, maintained by the National Council for Prescription Drug Programs. SCRIPT defines the specific data fields and message types — new prescription, refill request, refill response, cancellation, and others — that let a message generated inside one company’s EHR be read correctly by a completely different company’s pharmacy system. The Centers for Medicare & Medicaid Services (CMS) has adopted SCRIPT as the required standard for e-prescribing under Medicare Part D, which is a major reason it became the de facto national standard rather than one of several competing formats.

Sitting underneath the standard is the network layer. Surescripts operates the dominant e-prescribing network in the U.S., connecting the large majority of retail pharmacies, EHR vendors, and payers so that a prescription generated in one system can find its way to essentially any pharmacy the patient chooses.

How Does an E-Prescription Actually Travel From Clinician to Pharmacy?

The workflow is straightforward from the outside, but several checks happen in the background:

  1. Order entry. The clinician (or, in many practices, a delegate acting under the clinician’s authority) selects the medication inside the EHR’s prescribing module, typically searching by drug name and selecting from a formulary-aware list.
  2. Clinical decision support checks. Before the prescription can be signed, the system typically runs it against the patient’s problem list, allergy list, and current medications, flagging drug-drug interactions, drug-allergy conflicts, and sometimes dosing that falls outside typical ranges.
  3. Formulary and benefit check. Many systems query the patient’s pharmacy benefit in real time, showing the clinician whether the drug is covered, what tier it falls into, and whether a lower-cost therapeutic alternative exists.
  4. Electronic signature. The clinician signs off, which for a standard (non-controlled) prescription usually requires nothing more than a system login already in place.
  5. Transmission. The prescription is converted into a SCRIPT-standard message and routed through the network to the pharmacy the patient selected — commonly the one on file from a previous visit, or one chosen at the point of prescribing.
  6. Receipt and fill. The pharmacy’s system receives the structured message directly into its dispensing queue, without anyone re-keying the drug name, dose, or directions from a paper page or a faxed image.

Because the data arrives structured rather than as free text or a scanned image, pharmacy staff spend less time interpreting handwriting or calling the prescriber’s office to clarify an ambiguous order — one of the more consistently cited benefits of e-prescribing over paper.

What Makes EPCS Different — and Why Is It More Locked Down?

Prescriptions for controlled substances — Schedule II drugs like oxycodone and Adderall, and Schedule III-V drugs like some benzodiazepines and testosterone products — historically could not be transmitted electronically at all. Federal law required these to be issued on paper (or, in limited cases, called in or faxed under specific conditions) because of the abuse and diversion risk associated with these drugs.

That changed with a Drug Enforcement Administration (DEA) interim final rule, effective June 1, 2010, which gave practitioners the option — not the obligation — to prescribe controlled substances electronically, provided the prescriber’s software and the pharmacy’s receiving system met a specific set of security requirements. That option is what the industry refers to as EPCS.

The Two-Factor Authentication Requirement

The centerpiece of the DEA’s EPCS rule is a two-factor authentication requirement at the moment a controlled substance prescription is signed. The prescriber must authenticate using two of the following three factor categories:

  • Something the prescriber knows — a password or PIN.
  • Something the prescriber has — a hard cryptographic token or a one-time-password-generating device or app.
  • Something the prescriber is — a biometric, such as a fingerprint, meeting federal accuracy standards.

A username and password alone is not sufficient under the rule; the prescriber has to combine that knowledge factor with a possession or biometric factor specifically at the point of signing a controlled substance order. Hard tokens used for this purpose must meet a specific federal cryptographic security standard, and any biometric method must meet a defined false-match-rate threshold.

Identity Proofing Before Anyone Gets Credentials

Before a prescriber can even be issued EPCS credentials, the DEA rule requires identity proofing — a vetting process, conducted either by an approved third-party credential service provider or, for institutional settings, by the healthcare organization’s own credentialing staff, confirming the person requesting access is who they claim to be. This step is meant to prevent someone from fraudulently obtaining prescribing credentials under another practitioner’s name.

Software and Pharmacy Obligations

The prescriber isn’t the only party with obligations under EPCS. The software application itself must be audited or certified by an approved third-party auditor confirming it meets the DEA’s technical requirements around record integrity, logging, and access control. On the receiving end, pharmacies must have systems capable of accepting the electronic controlled-substance transaction without converting it to fax or paper somewhere in the process, and they must retain electronic records for a defined retention period.

What’s Driving Adoption?

A handful of forces have pushed both standard e-prescribing and EPCS specifically toward becoming the norm rather than the exception:

Federal Incentive Programs

The Medicare Part D e-prescribing incentive program, and later the Medicare and Medicaid EHR Incentive Programs (the “Meaningful Use” programs), tied a portion of provider payment to e-prescribing usage, giving practices a direct financial reason to adopt certified systems rather than continuing to hand-write or fax prescriptions.

State-Level Mandates Driven by the Opioid Crisis

Separately from federal incentive programs, a growing number of states have passed their own laws requiring electronic prescribing for some or all controlled substances, rather than merely permitting it as the DEA rule does at the federal level. New York’s I-STOP law was an early and widely cited example, phasing in a mandate for electronic prescribing of most controlled substances. Other states have followed with their own mandates and timelines, meaning the practical requirement a given prescriber faces often depends more on state law than on the federal EPCS rule alone.

Network Effects

As the share of pharmacies and EHRs connected to e-prescribing networks like Surescripts climbed, the value of adopting for any individual holdout practice increased — there was less reason to keep a fax machine running once virtually every neighborhood pharmacy could receive transactions electronically. Surescripts has reported that the substantial majority of prescriptions nationally are now routed electronically, reflecting how far adoption has progressed from the paper- and fax-dominated norm of the previous decade.

What Are the Real Benefits?

Fewer Errors From Illegible or Ambiguous Orders

The most frequently cited benefit of e-prescribing is the elimination of transcription errors tied to handwriting. When a prescription arrives as structured data rather than a handwritten note, a pharmacist doesn’t have to guess whether a decimal point is a stray mark or whether a drug name similar to another was intended. Multiple published comparisons of handwritten versus electronic prescriptions have found meaningfully lower error rates with electronic orders, and some studies have reported measurable declines in adverse drug events tied to e-prescribing, though results vary by setting and are not uniform across every error category.

Real-Time Clinical Checks

Drug interaction alerts, allergy checks, and dose-range warnings can only run automatically when a prescription is entered into a structured system — they simply don’t exist for a prescription written on a paper pad. This gives e-prescribing an inherent safety-net capability that paper cannot replicate.

Formulary Transparency at the Point of Care

Real-time benefit information lets a clinician see, before the patient leaves the room, whether a drug is covered and what it will likely cost the patient — reducing the number of prescriptions that later get rejected or substituted at the pharmacy counter, which used to require a callback to the prescriber’s office.

Reduced Diversion Risk for Controlled Substances

Because EPCS requires two-factor authentication and identity-proofed credentials, it closes off some of the fraud vectors associated with paper prescription pads — such as stolen or forged prescription blanks — that have historically been exploited for prescription drug diversion.

Where Does E-Prescribing Still Fall Short?

E-prescribing is not a solved problem, and it’s worth being honest about the gaps.

Alert Fatigue

Systems that fire a warning for every possible interaction, regardless of clinical significance, train clinicians to click through alerts reflexively. When a genuinely dangerous interaction is buried among dozens of low-value warnings, the safety benefit of decision support erodes. This is widely recognized as one of the more persistent unsolved problems in clinical informatics generally, not just e-prescribing specifically.

Incomplete Interoperability

Not every EHR implements every field or transaction type in the SCRIPT standard identically, and free-text fields (particularly for dosing instructions on compounded or unusual regimens) can still introduce ambiguity that structured data was supposed to eliminate. Cross-vendor transmission works far better than it did a decade ago, but it is not flawless.

Workflow Friction From EPCS Authentication

Two-factor authentication adds a deliberate step to the prescribing workflow specifically to make diversion harder — which means it also makes prescribing controlled substances slightly slower and more cumbersome than prescribing a non-controlled drug, especially in high-volume settings like emergency departments. Token loss, expired credentials, and identity-proofing renewal are recurring administrative headaches for practices supporting EPCS.

Adoption Gaps at Smaller Pharmacies and Practices

While large chain pharmacies and hospital-affiliated practices adopted e-prescribing and EPCS relatively quickly, some smaller independent pharmacies and solo or rural practices have lagged, sometimes due to the cost of certified software or limited IT support, creating pockets where paper or fax workflows persist longer than the national averages suggest.

It Does Not Eliminate Clinical Judgment Errors

E-prescribing reduces transcription and legibility errors, but it does not prevent a clinician from selecting the wrong drug from a lookalike list, misjudging a dose that falls within an allowed range but is still inappropriate for a specific patient, or missing a contraindication the system wasn’t designed to flag. The technology narrows one category of error; it does not replace clinical judgment.

Frequently Asked Questions

What is the difference between e-prescribing and EPCS?

E-prescribing refers broadly to transmitting any prescription electronically from a prescriber’s system to a pharmacy. EPCS is a specific, more tightly regulated subset covering controlled substances, requiring DEA-mandated safeguards such as identity proofing, audited software, and two-factor authentication at signing that standard e-prescribing does not require.

Is EPCS mandatory for all prescribers?

The DEA’s federal rule makes EPCS optional rather than mandatory, but a growing number of states have passed their own laws requiring electronic prescribing for controlled substances, so the actual requirement a prescriber faces often depends on state law.

What counts as an acceptable second authentication factor under EPCS?

Acceptable factors include something the prescriber has, such as a hard token or authentication device meeting federal cryptographic standards, or something the prescriber is, such as an approved biometric. A password alone, without a second factor, does not meet the DEA requirement.

Does e-prescribing eliminate medication errors entirely?

No. It significantly reduces errors tied to illegible handwriting and manual transcription, and several studies report meaningful reductions in adverse drug events, but it does not prevent clinical judgment errors, alert fatigue from over-warning, or every interoperability gap between different vendors’ systems.

Who operates the network that routes most U.S. e-prescriptions?

Surescripts operates the e-prescribing network used by the large majority of U.S. pharmacies, EHR vendors, and payers, though it is not the only such network, and prescriptions are formatted using the NCPDP SCRIPT standard so they can be read consistently regardless of which systems are on each end.

This article covers e-prescribing technology and regulatory requirements for informational purposes and does not constitute medical, legal, or compliance advice. Practices should confirm current DEA and state-specific requirements with qualified legal counsel before implementing EPCS.